VR as preparation for care as usual for patients with a panic disorder or social phobia.

Published: 18-06-2020 Last updated: 10-04-2024

The objective of this study is to investigate if VR as a pre-module improves the willingness to

start with exposure in vivo.

Ethical review Approved WMO **Status** Recruitment stopped

Health condition type Anxiety disorders and symptoms

Study type Interventional

Summary

ID

NL-OMON48032

Source

ToetsingOnline

Brief title

VR in patients (12-18 or 18+) with panic disorder or sociale phobia.

Condition

Anxiety disorders and symptoms

Synonym

Social phobia and panic disorder

Research involving

Human

Sponsors and support

Primary sponsor: ProPersona (Nijmegen)

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Panic Disorder, Social phobia, Virtual Reality

Outcome measures

Primary outcome

- willingness to take part in exposure in vivo

Measured with the Friedman-test (non-parametric).

When they differ significantly we will use post-hoc analyses (Wilcoxon Signed

Rank Test with a Bonferroni correction).

Secondary outcome

Anxiety Expectancy, activation of anxiety, approachability and course of symptoms (anxiety/depression) will be visual reproduced as descriptive statistics.

Study description

Background summary

CBT in adolescents and adults with a panic disorder or social phobia needs improvement.

Patients drop-out during the treatment or it's difficult to motivate for exposure in vivo to anxiety induced environments.

Virtual reality seems to be an promising intervention. A lot of studies studied the effects of VR as a treatment for anxiety disorders.

The objective of this study is to investigate if VR as a pre-module improves the willingness to start with exposure in vivo.

Study objective

The objective of this study is to investigate if VR as a pre-module improves the willingness to start with exposure in vivo.

Study design

The study design which will be used for this study is a single casedesign with repeated measures.

Intervention

Four VR sessions in which participants will be exposed to public traffic, a supermarket, a shopping district and a party in the garden.

Study burden and risks

The risk of participation in this study can be cybersickness. Participants will be informed about this and it's always a possibility to stop their participation in this study.

Contacts

Public

ProPersona (Nijmegen)

Tarweweg 2 Nijmegen 6534AM NL

Scientific

ProPersona (Nijmegen)

Tarweweg 2 Nijmegen 6534AM NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years) Adolescents (16-17 years)

3 - VR as preparation for care as usual for patients with a panic disorder or social ... 13-05-2025

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- DSM-5 diagnosis: panic disorder or social phobia, measured with the MINI KID (adolescents) or MINI (adults)
- Age between 12 and 18 (adolescents) of 18+

Exclusion criteria

- patients are diagnosed with a severe depressive disorder for which they need immediate treatment (measured with the MINI or MINI KID)
- patients are diagnosed with a psychosis for which they need immediate treatment (measured with the MINI or MINI KID)
- Mental retardation (IQ below 70)
- Substance abuse or dependence or alcohol abuse or dependence
- Psychofarmacology is changed in the last 8 weeks

Study design

Design

Study type: Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

Recruitment

NI

Recruitment status: Recruitment stopped

Start date (anticipated): 07-12-2020

Enrollment: 24

Type: Actual

Ethics review

Approved WMO

Date: 18-06-2020

Application type: First submission

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL72392.091.19